Pegzilarginase
- Generic Name
- Pegzilarginase
- Brand Names
- Loargys
- Drug Type
- Biotech
- CAS Number
- 1659310-95-8
- Unique Ingredient Identifier
- 4YV4KW88GD
- Background
Pegzilarginase is under investigation in clinical trial NCT02488044 (A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency).
Pegzilarginase in Subjects <24 Months Old with Arginase 1 Deficiency
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Immedica Pharma AB
- Target Recruit Count
- 3
- Registration Number
- NCT06582524
- Locations
- 🇦🇹
Univ. Klinik für Kinder- und Jugendheilkunde Medizinische Universität, Graz, Austria
🇬🇧Bradford Royal Infirmary Duckworth Lane, Bradford, United Kingdom
🇵🇹Unidade de Doenças Metabólicas Pediatria, Hospital Santa Maria, Lisboa, Portugal
A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Aeglea Biotherapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT05676853
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
- Conditions
- Arginase I DeficiencyHyperargininemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Aeglea Biotherapeutics
- Target Recruit Count
- 32
- Registration Number
- NCT03921541
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Harvey Pediatrics, Rogers, Arkansas, United States
🇺🇸University of Florida College of Medicine, Gainesville, Florida, United States
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Aeglea Biotherapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT03378531
- Locations
- 🇵🇹
Centro Hospitalar S. Joao, Porto, Portugal
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇨🇦The Hospital for Sick Children, Toronto, Ontario, Canada
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
- Conditions
- Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Aeglea Biotherapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT03371979
- Locations
- 🇺🇸
University of Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Aeglea Biotherapeutics
- Target Recruit Count
- 29
- Registration Number
- NCT02732184
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
🇺🇸Washington University Medical School, Saint Louis, Missouri, United States
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Aeglea Biotherapeutics
- Target Recruit Count
- 98
- Registration Number
- NCT02561234
- Locations
- 🇺🇸
Massachusetts General, Boston, Massachusetts, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Aeglea Biotherapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT02488044
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇵🇹Centro Hospitalar S. Joao, Porto, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.